371 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
Forecasts or expressed any opinion or given any other form of assurance, and no independent registered public accounting firm assumes any responsibility … 14A, there can be no assurance that any parties will reach an agreement.
Insurance and Indemnification of Directors and Executive Officers
The Merger
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
or expressed any opinion or given any other form of assurance, and no independent registered public accounting firm assumes any responsibility … officers, as of the date of this Schedule 14A, there can be no assurance that any parties will reach an agreement.
Insurance and Indemnification
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
financial reporting (as defined in Rules 13a–15(f) and 15d–15(f) of the Exchange Act) sufficient to provide reasonable assurance regarding the reliability … ) of the Exchange Act) that provide reasonable assurance that all material information required to be disclosed by the Company in the reports that it files
8-K
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
financial reporting (as defined in Rules 13a–15(f) and 15d–15(f) of the Exchange Act) sufficient to provide reasonable assurance regarding the reliability … ) of the Exchange Act) that provide reasonable assurance that all material information required to be disclosed by the Company in the reports that it files
8-K
EX-1.1
i2b8 yf2z
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
3ilv6bk
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
hr04sbi2 5czo
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-10.1
qyfbpf ra3x15
2 May 23
Entry into a Material Definitive Agreement
5:01pm